All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | Antibody Clone | Antibody Host | Receptor Construction | Vector Type | Targeting Cell Type | CAR Vector Type | Inquiry & Datasheet |
CAR-YF456 | Anti-CD20×CD47 (2B8×B6H12) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | 2B8 | Mouse | scFv (CD20)-scFv (CD47)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF458 | Anti-CD20×CD47 (Rituximab×B6H12) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF459 | Anti-CD20×CD47 (Rituximab×Hu5F9-G4) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF460 | Anti-CD20×CD47 (Rituximab×CC-90002) h(CD28-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD28-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF503 | Anti-CD20×CD47 (2B8×B6H12) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | 2B8 | Mouse | scFv (CD20)-scFv (CD47)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF505 | Anti-CD20×CD47 (Rituximab×B6H12) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF506 | Anti-CD20×CD47 (Rituximab×Hu5F9-G4) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF507 | Anti-CD20×CD47 (Rituximab×CC-90002) h(41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF550 | Anti-CD20×CD47 (2B8×B6H12) h(CD3ζ) TanCAR, pCDCAR1 | Human | 2B8 | Mouse | scFv (CD20)-scFv (CD47)-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF552 | Anti-CD20×CD47 (Rituximab×B6H12) h(CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF553 | Anti-CD20×CD47 (Rituximab×Hu5F9-G4) h(CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF554 | Anti-CD20×CD47 (Rituximab×CC-90002) h(CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF597 | Anti-CD20×CD47 (2B8×B6H12) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | 2B8 | Mouse | scFv (CD20)-scFv (CD47)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF599 | Anti-CD20×CD47 (Rituximab×B6H12) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF600 | Anti-CD20×CD47 (Rituximab×Hu5F9-G4) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF601 | Anti-CD20×CD47 (Rituximab×CC-90002) h(CD28-41BB-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD28-41BB-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF644 | Anti-CD20×CD47 (2B8×B6H12) h(CD28-OX40-CD3ζ) TanCAR, pCDCAR1 | Human | 2B8 | Mouse | scFv (CD20)-scFv (CD47)-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF646 | Anti-CD20×CD47 (Rituximab×B6H12) h(CD28-OX40-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF647 | Anti-CD20×CD47 (Rituximab×Hu5F9-G4) h(CD28-OX40-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD28-OX40-CD3ζ | Lentiviral vector | T Cell | ||
CAR-YF648 | Anti-CD20×CD47 (Rituximab×CC-90002) h(CD28-OX40-CD3ζ) TanCAR, pCDCAR1 | Human | Rituximab | Mouse | scFv (CD20)-scFv (CD47)-CD28-OX40-CD3ζ | Lentiviral vector | T Cell |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION